Skip to content

Ketamine: all studies

Page 365 of 449: studies 3,641 to 3,650 of 4,486, newest first. Back to the ketamine overview

Research

LLM-Augmented Therapy Normalization and Aspect-Based Sentiment Analysis for Treatment-Resistant Depression on Reddit

arXiv Preprint Archive March 12, 2026 Yuxin Zhu, Sahithi Lakamana, Masoud Rouhizadeh et al. preprint

Treatment-resistant depression (TRD) is a severe form of major depressive disorder in which patients do not achieve remission despite multiple adequate treatment trials. Evidence across pharmacologic options for TRD remains limited, and trials often do not fully capture patient-reported tolerability. Large-scale online peer-support narratives therefore offer a complementary lens on how patients...

TERAPIAS EMERGENTES COM PSICOTRÓPICOS EM TRANSTORNOS PSIQUIÁTRICOS

Editora Pasteur eBooks March 11, 2026 Ana Carolina Baldi Pasqualini, Henrique Wojciechowski Osorio, Veridiana Powarczuk et al.

Introdução: Os transtornos psiquiátricos representam um importante desafio na saúde pública mundial, com impacto significativo na qualidade de vida, funcionalidade e mortalidade dos pacientes. Embora os psicofármacos tradicionais, como antidepressivos, antipsicóticos e estabilizadores de humor sejam amplamente utilizados, muitos indivíduos apresentam resposta insatisfatória, falha terapêutica...

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

Research Square March 10, 2026 Giammarco di Gregorio, Sophia Basset, Harjot Manmohan et al. preprint

Abstract Depression and anxiety affect one in five adults, with age affecting prevalence. While clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan. We conducted a cross-sectional...

Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report

Research Square March 8, 2026 Sachin Shah, Hamilton Morrin preprint

Abstract Background: This case describes a substance-induced manic episode with psychotic features in which interaction with an AI (artificial intelligence) chatbot appeared to corroborate and reinforce the patient’s delusional thought content and to contradict medical advice. Excerpts from the patient’s interactions with the AI chatbot provide novel clinical insight into this phenomenon, which...

5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions

PLoS One March 6, 2026 Caden Poh, Cheyanne Head, John-Jose Nunez et al. 1 citation

Bipolar disorder (BD) is a prevalent mood disorder that can be associated with serious personal, societal, and economic costs. Growing attention is being paid to the importance of including the experiences of people living with BD in research and healthcare system advancement. However, there is still much to be learned about what people with BD are prioritizing, and where their needs are not...

Recreational drug poisonings reported to six European poison centres from 2021 to 2024

Clinical Toxicology March 4, 2026 Laura Hondebrink, Katrin Faber, Aza Kader et al. 1 citation

INTRODUCTION: Recreational drug poisonings pose a growing public health concern. European-level data remain limited, although poison centres are well placed to monitor related health incidents. This study analysed temporal trends in recreational drug poisonings reported to six European poison centres. METHODS: Aggregated retrospective data were collected over four years (2021-2024) from poison...

DOI: 10.1080/15563650.2026.2628073 (opens in new tab) Recreational use Public health Poison control Recreational drug use +6

Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review

American Journal of Health-System Pharmacy March 4, 2026 Jennifer E. Thomas, Anna Dellarole, Robin J Jacobs

MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under supervision may lead to improvements in PTSD symptoms, with the medications being generally well tolerated. However, caution should be used when interpreting study results due to limitations such as treatment expectancy effect and the potential for...

DOI: 10.1093/ajhp/zxag062 (opens in new tab) MDMA Psilocybin Expectancy theory Posttraumatic stress +5

Marked Improvement in Treatment-Intolerant Obsessive-Compulsive Disorder in an Adolescent Using a Glutamatergic Regimen With Dextromethorphan, Piracetam, and Goldenseal Root.

Cureus March 3, 2026 Ngo Cheung

A 16-year-old boy with severe obsessive-compulsive disorder (OCD), characterized by health-focused obsessions, intrusive ruminations, derealization, and significant functional impairment, failed to tolerate standard serotonergic agents (escitalopram, fluoxetine) and bupropion due to worsening anxiety, somatic concerns, or headaches. An oral glutamatergic regimen was initiated with...

DOI: 10.7759/cureus.104617 (opens in new tab) Full text (opens in new tab) Ampa receptor Herbal drugs Nmda receptor antagonist Obsessive-Compulsive Disorder OCD +2

The mPFC molecular clock mediates the effects of sleep deprivation on depression-like behavior and regulates sleep consolidation and homeostasis

Molecular Psychiatry March 1, 2026 Wilf Gardner, David H. Sarrazin, Martin Balzinger et al.

Disruptions in sleep, circadian rhythms, and neural plasticity are closely linked to the pathophysiology and treatment of depression. Acute sleep deprivation (SD) produces rapid but transient antidepressant effects, yet the underlying mechanisms remain poorly understood. Using a mouse model of stress-induced depression, we found altered sleep architecture, impaired sleep homeostasis, and...

Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.

Molecular and cellular neurosciences March 1, 2026 Mustafa M Shokr, Mohamed N Fawzy, Ahmed M Abdelaziz

Neuroplasticity refers to the ability of the brain to modify synaptic connections and reorganize neural circuits, underpinning cognitive function, emotional regulation, and recovery from injury. Recent advances have redefined adult neuroplasticity as more dynamic and therapeutically accessible than previously thought, spurring investigation into pharmacological interventions that can augment...

DOI: 10.1016/j.mcn.2026.104076 (opens in new tab) Full text (opens in new tab) Neuroplasticity Ampa receptor trafficking Multi-omics modeling Nitric oxide signaling +1